Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Radiopharmaceuticals

Volume 1 Issue 3
ISSN: 1874-4710
eISSN: 1874-4729


   All Titles

  Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy
  pp.203-208 (6) Authors: Oyvind S. Bruland, Thora J. Jonasdottir, Darrell R. Fisher, Roy H. Larsen
doi: 10.2174/1874471010801030203

The radiobiological and radiochemical properties of radium-223 (223Ra, T1/2 = 11.4 d) render this alpha-emitting radionuclide promising for targeted cancer therapy. Together with its short-lived daughters, each 223Ra decay produces four alpha-particle emissions which enhance therapy effectiveness at the cellular level. In this paper, we review the recently published data reported for pre-clinical and clinical use of 223Ra in cancer treatment. We have evaluated two distinct chemical forms of 223Ra in vivo: 1) cationic 223Ra as dissolved RaCl2, and 2) liposome-encapsulated 223Ra. Cationic 223Ra seeks metabolically active osteoblastic bone and tumor lesions with high uptake and strong binding affinity based on its similarities to calcium. Based on these properties, we have advanced the clinical use of 223Ra for treating bone metastases from breast and prostate cancer. The results show impressive anti-tumor activity and improved overall survival in hormone-refractory prostate cancer patients with bone metastases. In other studies, we have evaluated the biodistribution and tumor uptake of liposomally encapsulated 223Ra in mice with human osteosarcoma xenografts, and in dogs with spontaneous osteosarcoma and associated soft tissue metastases. Results indicate excellent biodistributions in both species. In dogs, we found considerable uptake of liposomal 223Ra in cancer metastases in multiple organs, resulting in favorable tumor- to-normal soft tissue ratios. Collectively, these findings show an outstanding potential for 223Ra as a therapeutic agent.

  Keywords: Cancer therapy, radionuclide, alpha-emitter
  Affiliation: Department of Radiation Biology, The Norwegian Radium Hospital, University of Oslo, Montebello, N-0310 Oslo, Norway.
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers


  Copyright © 1994 - 2015   Bentham Science Publishers